Insights - An independent advisory committee to the U.S. FDA voted in favor of approving Vertex Pharmaceuticals’ (VRTX) new treatment for Cystic Fibrosis, Orkambi, on Tuesday afternoon. The … Continue Reading
Read NowInsights - Alexion Pharmaceuticals (ALXN) is buying fellow ultra orphan drug developer Synageva (GEVA) for $8.4 billion. Alexion will pay $115 in cash and 0.6581 Alexion shares … Continue Reading
Read NowInsights - The FDA just doesn’t want to meet with AcelRx Pharmaceuticals (ACRX). Reported alongside the company’s first quarter financial update, AcelRx’s request for a Type B … Continue Reading
Read NowInsights - Shares of Pacira Pharmaceuticals (PCRX) took it on the chin at Thursday’s open as the company completely removed sales guidance for its only marketed product, Exparel. … Continue Reading
Read NowRecap - The first big news ahead of the American Association for Cancer Research’s (AACR) annual conference hit on Friday morning when Bristol-Myers Squibb (BMY) reported that … Continue Reading
Read NowInsights - An experimental stem cell treatment from Athersys Inc. (ATHX) failed to improve recovery in patients who had experienced a stroke. ATHX dropped 50% with the data release. … Continue Reading
Read NowInsights - Aduro Biotech (ADRO) begins trading on Wednesday morning at 10:25 ET having completed a $119 million IPO that values the immunotherapy company at just over … Continue Reading
Read Now
